TOT Biopharm Company Ltd has opened a new factory in eastern China.

           Stage one of its new high-tech production factory complex in the Suzhou Industrial Park has now been completed, with an inauguration ceremony being held in November.

           The $100 million factory will specialise in the research and development, production and marketing of anti-cancer drugs and represents a milestone in the cooperation between the biopharmaceutical sectors in mainland China and Taiwan.

           As such, the inauguration ceremony was attended by business leaders from both regions, including Wang Shaobang, deputy director of the Taiwan Affairs Office of Jiangsu Province; Yang Zhiping, director of Suzhou Industrial Park; and Gao Konglian, deputy chairman of Straits Exchange Foundation.

           The first stage of the new factory complex provides manufacturing facilities for an oral anti-cancer drug, alongside production facilities for cytotoxics, non-cytotoxics and an injected anti-cancer drug, and a GMP bio pilot plant.

           TOT Biopharm will now commence construction on the second stage of its new factory complex, providing additional production capacity.